Abstract
Irritable bowel syndrome (IBS) is one of the most common disorders in gastroenterology, affecting 10–15 % of the US population and accounting for one-quarter to one-half of all visits to digestive health specialists. With such a high prevalence, it may be inferred that a significant number of patients with ulcerative colitis (UC) also suffer from coexisting IBS. Indeed, it is widely believed that the prevalence of IBS is greater in patients with inflammatory bowel disease (IBD), affecting an estimated one-third of UC patients in remission. Recent research demonstrating a possible association between low-grade inflammation and IBS highlights the interconnecting relationship between inflammatory and functional disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sandler RS, Drossman DA, Nathan HP, et al. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction. Gastroenterology. 1984;87:314–8.
Isgar B, Harman M, Kaye M, et al. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut. 1983;24:190–2.
Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97(2):389–96.
Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci. 2004;49(3):469–74.
Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010;105(8):1788. 1789-94; quiz 1795. doi: 10.1038/ajg.2010.156. Epub 2010 Apr 13.
Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology. 1980;79:283–8.
Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms after diagnosis—how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4:614–20.
Ansari R, Attari F, Razjouyan H, et al. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol. 2008;20:46–50.
Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. Mol Med Rep. 2014;10(1):522–6.
Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn’s disease and ulcerative colitis. Neurogastroenterol Motil. 1998;10:189–202.
Shanahan F. Enteric neuropathology and inflammatory bowel disease. Neurogastroenterol Motil. 1998;10:185–7.
Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology. 1996;111:1683–99.
MacPherson BR, Shearon NL, Pfeiffer CJ. Experimental diffuse colitis in cats: observations on motor changes. J Surg Res. 1978;25:42–9.
Barbara G, Vallance BA, Collins SM. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology. 1997;113:1224–32.
Rao SS, Read NW. Gastrointestinal motility in patients with ulcerative colitis. Scand J Gastroenterol Suppl. 1990;172:22–8.
Farthing MJ, Lennard-Jones JE. Sensibility of the rectum to distension and the anorectal distension reflex in ulcerative colitis. Gut. 1978;19:64–9.
Manousos ON, Salem SN. Abnormal motility of the small intestine in ulcerative colitis. Gastroenterologia. 1965;104:249–57.
Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity, and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163–73.
Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med. 1962;31:307–22.
Drossman DA. Mind over matter in the postinfective irritable bowel. Gut. 1999;44:306–7.
Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.
Spiegel B. Questioning the bacterial overgrowth hypothesis in irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol. 2011;9:461–9.
Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology. 2014;146(6):1554–63.
Schmidt CM, Horton KM, Sitzmann JV, et al. Simple radiographic evaluation of ileoanal pouch volume. Dis Colon Rectum. 1996;39:66–73.
Bernstein CN, Rollandelli R, Niazi N, et al. Characterization of afferent mechanisms in ileoanal pouches. Am J Gastroenterol. 1997;92:103–8.
Shen B, Achkar JP, Lashner BA, et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol. 2002;97:972–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ginsburg, P.M., Bayless, T.M. (2014). Management of Irritable Bowel Syndrome in the Patient with Ulcerative Colitis. In: Lichtenstein, G. (eds) Medical Therapy of Ulcerative Colitis. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1677-1_40
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1677-1_40
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1676-4
Online ISBN: 978-1-4939-1677-1
eBook Packages: MedicineMedicine (R0)